Effects of metformin and statins on outcomes in men with castration-resistant metastatic prostate cancer: Secondary analysis of COU-AA-301 and COU-AA-302
dc.contributor.author | Wilson, B. E. | |
dc.contributor.author | Armstrong, A. J. | |
dc.contributor.author | de Bono, J. | |
dc.contributor.author | Sternberg, C. N. | |
dc.contributor.author | Ryan, C. J. | |
dc.contributor.author | Scher, H. I. | |
dc.contributor.author | Smith, M. R. | |
dc.contributor.author | Rathkopf, D. | |
dc.contributor.author | Logothetis, C. J. | |
dc.contributor.author | Chi, K. N. | |
dc.contributor.author | Jones, R. J. | |
dc.contributor.author | Saad, F. | |
dc.contributor.author | De Porre, P. | |
dc.contributor.author | Tran, N. | |
dc.contributor.author | Hu, P. | |
dc.contributor.author | Gillessen, Silke | |
dc.contributor.author | Carles, J. | |
dc.contributor.author | Fizazi, K. | |
dc.contributor.author | Joshua, A. M. | |
dc.date.accessioned | 2022-06-22T07:18:29Z | |
dc.date.available | 2022-06-22T07:18:29Z | |
dc.date.issued | 2022 | en |
dc.identifier.citation | Wilson BE, Armstrong AJ, de Bono J, Sternberg CN, Ryan CJ, Scher HI, et al. Effects of metformin and statins on outcomes in men with castration-resistant metastatic prostate cancer: Secondary analysis of COU-AA-301 and COU-AA-302. European Journal of Cancer. Elsevier BV; 2022.` | en |
dc.identifier.pmid | 35568679 | en |
dc.identifier.doi | 10.1016/j.ejca.2022.03.042 | en |
dc.identifier.uri | http://hdl.handle.net/10541/625309 | |
dc.description.abstract | Background: The associations of metformin and statins with overall survival (OS) and prostate specific antigen response rate (PSA-RR) in trials in metastatic castration-resistant prostate cancer remain unclear. Objective: To determine whether metformin or statins ± abiraterone acetate plus prednisone/prednisolone (AAP) influence OS and PSA-RR. Design, setting and participant: COU-AA-301 and COU-AA-302 patients were stratified by metformin and statin use. Cox proportional hazards models were used to estimate hazards ratio (HR) stratified by concomitant medications, and a random effects model was used to pool HR. We compared PSA-RR using Chi χ2 test. Results: In COU-AA-301-AAP, metformin was associated with improved PSA-RR (41.1% versus 28.6%) but not prolonged OS. In COU-AA-301-placebo-P, there was no association between metformin and prolonged OS or PSA-RR. In COU-AA-302-AAP, metformin was associated with prolonged OS (adjHR 0.69, 95% CI 0.48-0.98) and improved PSA-RR (72.7% versus 60.0%). In COU-AA-302-P, metformin was associated with prolonged OS (adjHR 0.66, 95% CI 0.47-0.93). In pooled analysis, OS was prolonged among those treated with metformin (pooled HR 0.77, 95% CI 0.62-0.95).In COU-AA-301-AAP, statins were associated with an improved OS (adjHR 0.76, 95% CI 0.62-0.93), while there was no difference in COU-AA-301-P. There was no association with statins and OS in either COU-AA-302 groups. When pooling HR, OS was prolonged among those treated with statins (pooled HR 0.78, 95% CI 0.68-0.88). Conclusion: Within the limitations of post-hoc sub-analyses, metformin and statins are associated with a prolonged OS and increased PSA-RR, particularly in combination with AAP. | en |
dc.language.iso | en | en |
dc.relation.url | https://dx.doi.org/10.1016/j.ejca.2022.03.042 | en |
dc.title | Effects of metformin and statins on outcomes in men with castration-resistant metastatic prostate cancer: Secondary analysis of COU-AA-301 and COU-AA-302 | en |
dc.type | Article | en |
dc.contributor.department | Princess Margaret Cancer Centre, Toronto, Canada; Faculty of Medicine, University of New South Wales, Kensington, Australia; Kinghorn Cancer Centre, St Vincents Hospital, Darlinghurst, Sydney, Australia | en |
dc.identifier.journal | European Journal of Cancer | en |
dc.description.note | en] | |
refterms.dateFOA | 2022-06-22T08:35:19Z |